The renin-angiotensin system is central to the pathophysiology of a number of cardiovascular disorders. Most obviously this is so with renin secreting tumours, but the system is of central importance in other disorders such as scleroderma renal crisis and most cases of malignant hypertension. Activation of the renin-angiotensin system in unilateral renal artery stenosis is pivotal to the development of hypertension and the disturbances in electrolyte and volume balance -most particularly in the hyponatraemic-hypertensive syndrome. Likewise, stimulation of the renin-angiotensin system is an important contributor, amongst many other systems, to the pathophysiology of cardiac failure. In diabetic nephropathy, the renin-angiotensin system is
Introduction
It is 100 years since renin was discovered by Tigerstedt and Bergman. The importance of the reninangiotensin system in cardiovascular disease has been clarified greatly by experiments in animals, particularly involving unilateral renal artery stenosis, the development of techniques to measure levels of renin and angiotensin II in plasma, and more recently the manufacture of agents which block activity of the renin-angiotensin system. The most recent drug class available in clinical medicine involves the selective angiotensin II type-1 receptor blockers, the prototype being losartan.
Despite advances over the past 100 years, there is considerable uncertainty as to the importance of the renin-angiotensin system in some disorders, most particularly essential hypertension and its complications. Here the focus of uncertainty is whether or not the pathophysiological importance of the reninangiotensin system is reflected by circulating levels of renin or angiotensin II, and whether tissue levels of renin systems account for, or contribute to vascular and left ventricular hypertrophy, and in part through aldosterone secretion to fibrotic changes in cardiovascular tissues. Likewise, it is unclear whether the development of atheroma and thrombosis leading particularly to myocardial infarction but perhaps also to stroke, is hastened by the various actions of the renin-angiotensin system.
In this article we briefly examine our perception of the importance of the renin-angiotensin system in a range of cardiovascular disorders.
Renin secreting tumour
This rare condition, characterised by hypertension and hypokalaemia, is entirely accounted for by autonomous or semi-autonomous over-production of renin, usually from a haemangiopericytoma within the kidney. Removal of the tumour restores arterial pressure to normal and corrects the hypokalaemia. 1 Here is clear evidence that renin hypersecretion can induce a disorder of blood pressure control and electrolyte homeostasis.
Scleroderma renal crisis
In earlier years, scleroderma renal crisis was uniformly fatal. Bilateral nephrectomy and dialysis, or later the introduction of minoxidil-based anti-hypertensive treatment offered the only hope for survival. The advent of angiotensin-converting enzyme (ACE) inhibitors was associated with a striking improvement in survival 2 which firmly points to a pivotal role of intense activation of the renin-angiotensin system in the pathophysiology of this uncommon disorder.
Widespread arteriolar constriction within the kidney is presumed to account for vigorous activation of the circulating renin-angiotensin system in scleroderma renal crisis, and high circulating levels of angiotensin II exacerbate further the renal arteriolar constriction with a resulting malignant hypertension-like state. The ACE inhibitors are now the mainstay for the control of blood pressure and main-tenance of renal function. One would predict that angiotensin II type-1 receptor blockers likewise would break the vicious cycle of ever increasing renal vasoconstriction and a progressive decline in glomerular filtration in this disorder.
Unilateral renal artery stenosis and the hyponatraemic-hypertensive syndrome
Although many factors may contribute to a greater or lesser extent to the development of hypertension and perturbations of volume and electrolyte balance in unilateral renal artery stenosis, most would agree that the renin-angiotensin system is of central importance. This does not require that circulating levels of renin and angiotensin II are necessarily beyond the 'normal' range, since it is known that chronic over-production of renin or long-term intravenous infusion of angiotensin II results in a steady continuous rise in arterial pressure. The mechanisms underlying this slow pressor effect of angiotensin II have not been completely elucidated. 3 Whatever the explanation, it is clear that renin and angiotensin II levels in plasma within the normal range can sustain hypertension in unilateral renal artery stenosis. Certainly, normal levels of renin or angiotensin II do not rule out an important pathophysiologic role for this pressor system.
The hyponatraemic-hypertensive syndrome associated with unilateral renal ischaemia, has long been known. Nevertheless, most standard general medical textbooks and indeed specialist nephrology and hypertension textbooks rarely mention its existence. The largest series reported, to our awareness, is of six patients from Glasgow. 4 Characteristically, such patients have severe hypertension, evidence of volume depletion and gross activation of the reninangiotensin system.
Review of our experience of this disorder revealed over 30 examples (unpublished data). Most patients were elderly asthenic women who had smoked heavily for many years. Prominent presenting symptoms were headache, drowsiness or disordered consciousness, weakness, weight loss, thirst, polyuria and postural hypotension. The first dose of an ACE inhibitor in such patients can induce a vigorous and excessive fall in arterial pressure due to withdrawal of angiotensin II production in the presence of volume depletion. 5 We have found that cautious volume repletion with intravenous saline is occasionally necessary where ACE inhibitor therapy is being initiated. We found an inverse relationship between plasma sodium levels and circulating levels of plasma renin and aldosterone. Most of our patients had proteinuria. In this regard, angiotensin II experimentally has been shown to induce an increase in urine protein excretion. 6 Indeed, proteinuria into the nephrotic range is well recorded in unilateral renal artery stenosis, 7 and correction of the stenosis or administration of an ACE inhibitor usually returned protein excretion to normal. 8 Our view of the pathophysiology of this hyponatraemic-hypertensive syndrome is shown in Figure  1 , which is a slight modification of the proposal by Atkinson and colleagues. 5 Over-secretion of renin Figure 1 Proposed pathophysiology of the hyponatraemic-hypertensive syndrome in patients with unilateral renal ischaemia. High levels of angiotensin II induce hypertension of sufficient severity or rapidity to induce pressure natriuresis through the non-stenosed kidney, thereby inducing hypovolaemia which further increases renin secretion and contributes to overproduction of vasopressin (AVP) and stimulation of thirst. These factors, along with direct effects of angiotensin II on the kidney lead to hyponatraemia. High levels of angiotensin II also induce proteinuria and hyperaldosteronism, leading to hypokalaemia. The boxes indicate features likely to contribute to the development of symptoms.
and hence over-production of angiotensin II induces hypertension which, if severe or sudden, may induce a pressure natriuresis through the nonstressed kidney notwithstanding the antinatriuretic actions of aldosterone and angiotensin II. Hypovolaemia can stimulate vasopressin release and thirst as can high levels of angiotensin II itself. 9,10 These factors, along with a direct action of angiotensin II on the kidney to retain water in excess of sodium, presumably leads to hyponatraemia. As mentioned above, high levels of circulating angiotensin II can induce proteinuria. Under many circumstances, angiotensin II is the main secretagogue for aldosterone. Where there is volume depletion, as is typically seen in the hyponatraemic-hypertensive syndrome, the aldosterone response to angiotensin II is heightened. 11, 12 In our patients, aldosterone levels in plasma were often exceedingly high. Not surprisingly, hypokalaemia was almost uniformly seen, and one patient with a potassium level in plasma at 1.7 mmol/L presented to medical attention with recurrent ventricular tachycardia.
All features of the hyponatraemic-hypertensive syndrome are corrected by removal of the ischaemic kidney or correction of the ischaemia by balloon dilatation or stent insertion, or by the administration of ACE inhibitors. Of course, the therapeutic place of these latter drugs in unilateral renal ischaemia is debated, but in our experience control of arterial pressure is difficult and often impossible in the absence of an ACE inhibitor, usually in combination with a second or third anti-hypertensive drug.
In our view, the hyponatraemic-hypertensive syndrome associated with renal ischaemia is not at all uncommon. Clinical suspicion should be high in any hypertensive with hyponatraemia to ensure relevant investigations and appropriate management.
Heart failure
There is no doubt that the renin-angiotensin system is an important contributor to the pathophysiology of heart failure. As with unilateral renal artery stenosis, normal circulating levels of renin in untreated patients should not automatically lead to the conclusion that the system is unimportant. Even normal levels of circulating angiotensin II are likely to be inappropriate in patients with impaired left ventricular function as would normal levels of aldosterone. In untreated patients, frankly elevated levels of renin, angiotensin II and aldosterone are generally only seen in the later stages of the disorder. Powerful diuretic treatment is likely to be life-saving in the short term, but alone in the longer term induces stimulation of renin release and high circulating levels of angiotensin II and aldosterone. 13 In heart failure, angiotensin II is the major regulator of aldosterone. 13 The kidney response to aldosterone is altered in heart failure so that it does not 'escape' its sodium-retaining effects, 14 and it is probable that the kidney is hyper-responsive to the sodium-retaining effects of aldosterone. 15 The introduction of ACE inhibitors for the treatment of heart failure has been a major milestone in cardiovascular therapeutics. Not only do these drugs increase longevity but they also improve quality of life, reduce hospitalization rates and they are costeffective. These observations are not proof of the pathophysiologic importance of the renin-angiotensin system in heart failure, since the ACE inhibitors have actions beyond inhibition of angiotensin II formation. Nevertheless, the competitive receptor antagonist saralasin, at least in the short term, provided haemodynamic benefit in heart failure. 16 Furthermore, available evidence, though short of being definitive, suggests that losartan, the angiotensin II type-1 receptor blocker, has similar or greater efficacy compared with the ACE inhibitor captoprilat least in elderly patients with cardiac failure. 17 Heart failure is a disorder in which numerous neurohormonal systems are modified. Available evidence is that the renin-angiotensin system, whether through activation or maintenance of 'normal' production, is an important contribution to the pathophysiology.
Diabetic nephropathy
Activity of the renin-angiotensin system as reflected by circulating levels of renin, are rarely increased in patients with diabetes. For patients with diabetic nephropathy and/or hypertension, most studies show suppression of plasma renin levels. 18 Those with diabetic nephropathy typically have a volumeexpanded state, 18 and under these circumstances the pressor action of angiotensin II is heightened. 11, 12 Hence normal or low circulating levels of renin do not necessarily rule out an important circulatory effect. Furthermore, levels or activity of renin within the kidney may not necessarily be reflected by plasma levels of the enzyme.
Increasing evidence that blockade of the reninangiotensin systems using ACE inhibitors reduces urine protein excretion and preserves glomerular filtration rate more successfully than alternative forms of anti-hypertensive treatment, is consistent with the premise that the renin-angiotensin system is one contributor to the accelerated decline in kidney function in patients with diabetic nephropathy. Because the ACE inhibitors, as mentioned already, have actions beyond inhibition of angiotensin II formation, such data need not necessarily define a role for the renin system in diabetic nephropathy. In this regard, studies under way to compare the renoprotective effects of angiotensin II type-1 receptor blockers versus the ACE inhibitors will be particularly interesting.
Researchers have concentrated on the blood pressure, metabolic and renal sparing effects of ACE inhibitors in diabetic patients. Strangely, little attention has been directed to the potential beneficial effects of these drugs on diabetic retinopathy. In that some components of the renin-angiotensin system are well represented in the eye, perhaps especially so in diabetics with retinopathy, 19 and since uncontrolled studies suggest that ACE inhibition may reduce retinal permeability to fluorescein, 20 one might speculate that ACE inhibitors and angiotensin II type-1 receptor blockers will slow the rate of progression in diabetic retinopathy-perhaps to a greater extent than other forms of anti-hypertensive treatment.
Essential hypertension
The renin-angiotensin system as reflected by circulating levels of renin, is activated in a minority of young essential hypertensives, but with increasing age and level of arterial pressure there is an accelerated decline in activity compared with age-matched normotensives. 21 Most would view the renin-angiotensin system as one contributor to the level of arterial pressure in both essential hypertensives and in normotensives, but few would contend that overactivity of circulating or tissue renin systems is the cause of essential hypertension.
In that angiotensin II has been shown experimentally to be a growth factor, there is speculation that both vascular and ventricular hypertrophy, which is commonly seen in essential hypertension, is contributed to by the renin-angiotensin system as well as by blood pressure itself, and a myriad of other factors including obesity, increasing age and a high dietary sodium intake. In this regard, at least two meta-analyses suggest that anti-hypertensive drug treatment with ACE inhibitors reduces left ventricular hypertrophy more rapidly and perhaps more completely than alternative anti-hypertensive drug groups. 22, 23 This evidence is probably short of definitive, and additional studies are under way. Somewhat against a hypertrophic role of angiotensin II in essential hypertension is evidence from two small studies that the angiotensin II type-1 receptor blocker losartan, failed to reverse left ventricular hypertrophy in essential hypertensives. 24, 25 Other unpublished data, however, give contrary information, so this question remains an open one.
Perhaps the most contentious and uncertain area is whether the renin-angiotensin system contributes to the complications of hypertension, namely stroke and myocardial infarction through acceleration of the atheromatous process, an augmented vasculoproliferative response to injury, or via an enhanced tendency to thrombosis. Evidence from New York over some decades suggests that essential hypertensives with raised circulating levels of renin, are especially predisposed to myocardial infarction compared with those with normal and, especially, low levels of renin. 26, 27 Other workers have been unable to detect such a relationship. 28 This is an important issue since if such an association between activity of the renin system and atherogenesis or thrombosis exists, then agents which block the renin system or its activity should prove more protective against the complications of hypertension, in particular myocardial infarction but also stroke, than alternative forms of anti-hypertensive treatment, particularly those which stimulate activity of the renin-angiotensin system. Studies are under way to investigate this possibility. For example, an Australian trial in elderly hypertensives will compare the ACE inhibitor enalapril, with a thiazide diuretic. 29 If the ACE inhibitor proves more protective against myocardial ischaemic events than the thiazide, this would be supportive evidence of a link between the renin system and the atherogenic or thrombotic complications of essential hypertension. A negative outcome, however, would by no means rule out such an association since it may be one which develops over many years and even decades. Accordingly, comparative anti-hypertensive drugs trials may need to run for many years and even decades to define these possibilities.
Overview
The renin-angiotensin system is of central pathophysiologic importance in renin-secreting tumour scleroderma renal crisis and most cases of malignant hypertension. It is probably pivotal to the development of hypertension in most patients with unilateral renal artery stenosis and certainly in the hyponatraemic-hypertensive syndrome due to unilateral renal ischaemia, a disorder which deserves greater recognition. In heart failure, activity of the reninangiotensin system is one amongst a number of systems whose activity is important in the pathophysiology. Blockade of the renin system with ACE inhibitors, and probably with angiotensin II type-1 receptor blockers, increase longevity-which confirms that the renin system indeed plays a central pathophysiologic role. The system likewise is likely to play at least a supportive pathophysiologic role in diabetic nephropathy. In essential hypertension, there are more questions than answers in regard to the role of the renin system. Studies underway have the potential to clarify whether or not the reninangiotensin system contributes to the development of coronary heart disease beyond the level of arterial pressure.
